References
Key articles
American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern 2024. Feb 2025 [internet publication].Full text
National Institute for Health and Care Excellence. Age-related macular degeneration. Jan 2018 [internet publication].Full text
American Academy of Ophthalmology. Preferred practice pattern: retina summary benchmarks - 2024. Dec 2024 [internet publication].Full text
Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023 Apr 29;401(10386):1459-72. Abstract
Reference articles
1. Arnold JJ. Age-related macular degeneration: anti-vascular endothelial growth factor treatment. BMJ Clin Evid. 2016 Feb 24;2016:0701.Full text Abstract
2. Ferris FL 3rd, Wilkinson CP, Bird A, et al; Beckman Initiative for Macular Research Classification Committee. Clinical classification of age-related macular degeneration. Ophthalmology. 2013 Apr;120(4):844-51. Abstract
3. Sheth JU, Stewart MW, Narayanan R, et al. Macular neovascularization. Surv Ophthalmol. 2025 Jul-Aug;70(4):653-75. Abstract
4. American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern 2024. Feb 2025 [internet publication].Full text
5. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb;2(2):e106-16.Full text Abstract
6. GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e130-43.Full text Abstract
7. GBD 2019 Blindness and Vision Impairment Collaborators, Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021 Feb;9(2):e144-60.Full text Abstract
8. Vision Loss Expert Group of the Global Burden of Disease Study, GBD 2019 Blindness and Vision Impairment Collaborators. Global estimates on the number of people blind or visually impaired by age-related macular degeneration: a meta-analysis from 2000 to 2020. Eye (Lond). 2024 Aug;38(11):2070-82.Full text Abstract
9. Zhou M, Duan PC, Liang JH, et al. Geographic distributions of age-related macular degeneration incidence: a systematic review and meta-analysis. Br J Ophthalmol. 2021 Oct;105(10):1427-34.Full text Abstract
10. Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of age-related macular degeneration in the US in 2019. JAMA Ophthalmol. 2022 Dec 1;140(12):1202-08.Full text Abstract
11. Li JQ, Welchowski T, Schmid M, et al. Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis. Br J Ophthalmol. 2020 Aug;104(8):1077-84. Abstract
12. Rudnicka AR, Jarrar Z, Wormald R, et al. Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology. 2012 Mar;119(3):571-80. Abstract
13. Yonekawa Y, Miller JW, Kim IK. Age-related macular degeneration: advances in management and diagnosis. J Clin Med. 2015 Feb 12;4(2):343-59.Full text Abstract
14. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010 Dec 13;10:31.Full text Abstract
15. Chiu CJ, Chang ML, Zhang FF, et al. The relationship of major American dietary patterns to age-related macular degeneration.Am J Ophthalmol. 2014 Jul;158(1):118-27. Abstract
16. Ersoy L, Ristau T, Lechanteur YT, et al. Nutritional risk factors for age-related macular degeneration. Biomed Res Int. 2014 Jul;2014:413150.Full text Abstract
17. Chapman NA, Jacobs RJ, Braakhuis AJ. Role of diet and food intake in age-related macular degeneration: a systematic review. Clin Exp Ophthalmol. 2019 Jan;47(1):106-27. Abstract
18. Gastaldello A, Giampieri F, Quiles JL, et al. Adherence to the mediterranean-style eating pattern and macular degeneration: a systematic review of observational studies. Nutrients. 2022 May 12;14(10):2028.Full text Abstract
19. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016 Feb;48(2):134-43.Full text Abstract
20. Stradiotto E, Allegrini D, Fossati G, et al. Genetic aspects of age-related macular degeneration and their therapeutic potential. Int J Mol Sci. 2022 Oct 31;23(21):13280.Full text Abstract
21. Garcia-Garcia J, Usategui-Martin R, Sanabria MR, et al. Pathophysiology of age-related macular degeneration: implications for treatment. Ophthalmic Res. 2022;65(6):615-36.Full text Abstract
22. Blasiak J, Sobczuk P, Pawlowska E, et al. Interplay between aging and other factors of the pathogenesis of age-related macular degeneration. Ageing Res Rev. 2022 Nov;81:101735.Full text Abstract
23. Wong JHC, Ma JYW, Jobling AI, et al. Exploring the pathogenesis of age-related macular degeneration: a review of the interplay between retinal pigment epithelium dysfunction and the innate immune system. Front Neurosci. 2022 Nov 3;16:1009599.Full text Abstract
24. Kushwah N, Bora K, Maurya M, et al. Oxidative stress and antioxidants in age-related macular degeneration. Antioxidants (Basel). 2023 Jul 3;12(7):1379.Full text Abstract
25. Abokyi S, To CH, Lam TT, et al. Central role of oxidative stress in age-related macular degeneration: evidence from a review of the molecular mechanisms and animal models. Oxid Med Cell Longev. 2020 Feb 10;2020:7901270.Full text Abstract
26. Ruan Y, Jiang S, Gericke A. Age-related macular degeneration: role of oxidative stress and blood vessels. Int J Mol Sci. 2021 Jan 28;22(3):1296.Full text Abstract
27. Terao R, Ahmed T, Suzumura A, et al. Oxidative stress-induced cellular senescence in aging retina and age-related macular degeneration. Antioxidants (Basel). 2022 Nov 5;11(11):2189.Full text Abstract
28. Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024 Jan 9;331(2):147-57. Abstract
29. Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020 May;127(5):616-36.Full text Abstract
30. Tenbrock L, Wolf J, Boneva S, et al. Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives. Cell Tissue Res. 2022 Mar;387(3):361-75.Full text Abstract
31. Datta S, Cano M, Ebrahimi K, et al. The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD. Prog Retin Eye Res. 2017 Sep;60:201-18.Full text Abstract
32. Centers for Disease Control and Prevention. VEHSS modeled estimates: age-related macular degeneration (AMD). May 2024 [internet publication].Full text
33. Chua B, Flood V, Rochtchina E, et al. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol. 2006 Jul;124(7):981-6.Full text Abstract
34. Pameijer EM, Heus P, Damen JAA, et al. What did we learn in 35 years of research on nutrition and supplements for age-related macular degeneration: a systematic review. Acta Ophthalmol. 2022 Dec;100(8):e1541-52.Full text Abstract
35. Chiu CJ, Klein R, Milton RC, et al. Does eating particular diets alter the risk of age-related macular degeneration in users of the age-related eye disease study supplements? Br J Ophthalmol. 2009 Sep;93(9):1241-6. Abstract
36. Meng XT, Shi YY, Hong-Yan Z. Dietary omega-3 LCPUFA intake in the prevention of neovascular age-related macular degeneration: a systematic review and meta-analysis. Nutr Hosp. 2022 Aug 25;39(4):910-5.Full text Abstract
37. Prevent Blindness America. How often should I have an eye exam? 2013 [internet publication].Full text
38. American Academy of Ophthalmology. Eye exam and vision testing basics. Feb 2024 [internet publication].Full text
39. National Institute for Health and Care Excellence. Age-related macular degeneration. Jan 2018 [internet publication].Full text
40. American Academy of Ophthalmology. Preferred practice pattern: retina summary benchmarks - 2024. Dec 2024 [internet publication].Full text
41. Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023 Apr 29;401(10386):1459-72. Abstract
42. Apte RS. Age-related macular degeneration. N Engl J Med. 2021 Aug 5;385(6):539-47.Full text Abstract
43. Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014 Sep;98(9):1144-67.Full text Abstract
44. Javed A, Khanna A, Palmer E, et al. Optical coherence tomography angiography: a review of the current literature. J Int Med Res. 2023 Jul;51(7):3000605231187933.Full text Abstract
45. Batıoğlu F, Yanık Ö, Demirel S, et al. Clinical use of optical coherence tomography angiography in retinal diseases. Diagnostics (Basel). 2023 May 22;13(10):1820.Full text Abstract
46. Yadav S, Parry DG, Beare NAV, et al. Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians. Br J Ophthalmol. 2017 Oct;101(10):1377-80. Abstract
47. Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016 Jan;50:1-24. Abstract
48. Bakri SJ, Bektas M, Sharp D, et al. Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm. 2023 May;29(5-a suppl):S2-11.Full text Abstract
49. Armendariz BG, Chakravarthy U. Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era. Eye (Lond). 2024 Dec;38(17):3243-51.Full text Abstract
50. Rowland CJ, Lee LR. Ocular causes of visual distortions. Aust J Gen Pract. 2019 Aug;48(8):525-30.Full text Abstract
51. Greig EC, Duker JS, Waheed NK. A practical guide to optical coherence tomography angiography interpretation. Int J Retina Vitreous. 2020 Nov 13;6(1):55.Full text Abstract
52. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001 Oct;119(10):1417-36.Full text Abstract
53. US Preventative Services Task Force. Final recommendation statement - impaired visual acuity in older adults: screening. May 2022 [internet publication].Full text
54. Chou R, Bougatsos C, Jungbauer R, et al. Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Jun 7;327(21):2129-40.Full text Abstract
55. Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2015 Apr 9;2015(4):CD010015.Full text Abstract
56. Age-Related Eye Disease Study 2 Research Group. Lutein plus zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013 May 15;309(19):2005-15.Full text Abstract
57. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. Abstract
58. Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev. 2017 Jul 30;(7):CD000253.Full text Abstract
59. Mares-Perlman JA, Fisher AI, Klein R, et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol. 2001 Mar 1;153(5):424-32.Full text Abstract
60. Delcourt C, Cristol JP, Tessier F, et al. Age-related macular degeneration and antioxidant status in the POLA study. POLA Study Group. Pathologies Oculaires Liees a l'Age. Arch Ophthalmol. 1999 Oct;117(10):1384-90.Full text Abstract
61. Cho E, Stampfer MJ, Seddon JM, et al. Prospective study of zinc intake and the risk of age-related macular degeneration. Ann Epidemiol. 2001 Jul;11(5):328-36. Abstract
62. van Leeuwen R, Boekhoorn S, Vingerling JR, et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA. 2005 Dec 28;294(24):3101-7.Full text Abstract
63. Chew EY, Clemons TE, Agrón E, et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 report 28. JAMA Ophthalmol. 2022 Jul 1;140(7):692-98.Full text Abstract
64. Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023 Oct 21;402(10411):1434-48. Abstract
65. Khanani AM, Patel SS, Staurenghi G, et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1449-58. Abstract
66. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul;119(7):1388-98.Full text Abstract
67. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: Ninety-six-week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021 Jan;128(1):89-99.Full text Abstract
68. Gragoudas ES, Adamis AP, Cunningham ET Jr., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805-16. Abstract
69. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.Full text Abstract
70. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1419-31.Full text Abstract
71. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48.Full text Abstract
72. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013 Jul;27(7):787-94.Full text Abstract
73. Cébe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci. 2006 Mar;63(5):601-15.Full text Abstract
74. Heier JS, Khanani AM, Quezada Ruiz C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022 Feb 19;399(10326):729-40. Abstract
75. Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2019 Mar 4;(3):CD005139.Full text Abstract
76. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009 Sep;116(9):1731-9. Abstract
77. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011 Jun;118(6):1098-106. Abstract
78. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014 Jan;121(1):193-201.Full text Abstract
79. Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology. 2014 May;121(5):1092-101.Full text Abstract
80. Fallico M, Lotery AJ, Longo A, et al. Treat and extend versus fixed regimen in neovascular age related macular degeneration: a systematic review and meta-analysis. Eur J Ophthalmol. 2021 Sep;31(5):2496-504. Abstract
81. Chin-Yee D, Eck T, Fowler S, et al. A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol. 2016 Jul;100(7):914-7. Abstract
82. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009 Jan;116(1):57-65. Abstract
83. Song D, Liu P, Shang K, et al. Application and mechanism of anti-VEGF drugs in age-related macular degeneration. Front Bioeng Biotechnol. 2022;10:943915.Full text Abstract
84. Ohji M, Takahashi K, Okada AA, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173-87.Full text Abstract
85. Mitchell P, Holz FG, Hykin P, et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina. 2021 Sep 1;41(9):1911-20.Full text Abstract
86. Lanzetta P, Korobelnik JF, Heier JS, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23;403(10432):1141-1152.Full text Abstract
87. Moon BH, Kim Y, Kim SY. Twenty years of anti-vascular endothelial growth factor therapeutics in neovascular age-related macular degeneration treatment. Int J Mol Sci. 2023 Aug 21;24(16):13004.Full text Abstract
88. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020 Jan;127(1):72-84.Full text Abstract
89. Monés J, Srivastava SK, Jaffe GJ, et al. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER. Ophthalmology. 2021 Jul;128(7):1050-9.Full text Abstract
90. Novartis. Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program. May 2021 [internet publication].Full text
91. Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: phase 3a, multicenter, randomized, double-masked trial of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid. Ophthalmology. 2022 Sep;129(9):974-85. Abstract
92. Medicines and Healthcare products Regulatory Agency: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals. Jan 2022 [internet publication].Full text
93. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411. Abstract
94. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013 Oct 12;382(9900):1258-67.Full text Abstract
95. Moja L, Lucenteforte E, Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014 Sep 15;9(9):CD011230.Full text Abstract
96. Rahhal FM, Hu A, Humayun M, et al. ONS-5010 (bevacizumab-vikg) safety and efficacy in subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina. 2025 Mar;56(3):178-89.Full text Abstract
97. Waizel M, Todorova MG, Masyk M, et al. Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD. BMC Ophthalmol. 2017 May 23;17(1):79.Full text Abstract
98. Barthelmes D, Campain A, Nguyen P, et al. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration. Br J Ophthalmol. 2016 Dec;100(12):1640-5.Full text Abstract
99. Wong DT, Aboobaker S, Maberley D, et al. Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations. BMJ Open Ophthalmol. 2025 Jan 16;10(1):e001967.Full text Abstract
100. Specialist Pharmacy Service. Understanding biological and biosimilar medicines. Jun 2023 [internet publication].Full text
101. American Academy of Ophthalmology. The use of biosimilars in ophthalmic practice - 2022. Jan 2022 [internet publication].Full text
102. Specialist Pharmacy Service. Good governance when implementing ranibizumab biosimilar. Mar 2023 [internet publication].Full text
103. Specialist Pharmacy Service. The licence and supporting evidence for ranibizumab biosimilar. Mar 2023 [internet publication].Full text
104. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol. 1991 Aug;109(8):1109-14. Abstract
105. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Arch Ophthalmol. 1994 Apr;112(4):500-9. Abstract
106. Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020 Sep 1;138(9):935-42.Full text Abstract
107. Jackson TL, Chakravarthy U, Slakter JS, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study. Ophthalmology. 2015 Jan;122(1):138-45.Full text Abstract
108. Jackson TL, Desai R, Wafa HA, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial. Lancet. 2024 Jul 6;404(10447):44-54.Full text Abstract
109. Evans JR, Igwe C, Jackson TL, et al. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020 Aug 26;(8):CD004004.Full text Abstract
110. Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial. Ophthalmology. 2019 Aug;126(8):1141-1154.Full text Abstract
111. Holekamp NM, Campochiaro PA, Chang MA, et al. Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2022 Mar;129(3):295-307.Full text Abstract
112. Boyer D, Hu A, Warrow D, et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (Dry) age-related macular degeneration using the lumithera valeda light delivery system. Retina. 2024 Mar 1;44(3):487-97.Full text Abstract
113. Joo K, Mun YS, Park SJ, et al. Ten-year progression from intermediate to exudative age-related macular degeneration and risk factors: bundang AMD cohort study report 1. Am J Ophthalmol. 2021 Apr;224:228-37. Abstract
114. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991 Sep;109(9):1220-31. Abstract
115. Sunness JS, Rubin GS, Applegate CA, et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology. 1997 Oct;104(10):1677-91. Abstract
116. Hwang CK, Agrón E, Domalpally A, et al. Progression of geographic atrophy with subsequent exudative neovascular disease in age-related macular degeneration: AREDS2 report 24. Ophthalmol Retina. 2021 Feb;5(2):108-17.Full text Abstract
117. Maguire MG, Martin DF, Ying GS, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016 Aug;123(8):1751-61.Full text Abstract
118. Clemens CR, Eter N. Retinal pigment epithelium tears: risk factors, mechanism and therapeutic monitoring. Ophthalmologica. 2016;235(1):1-9. Abstract
119. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006 Mar;113(3):363-72. Abstract
120. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006 Jul;142(1):1-9. Abstract
121. Yang JM, Jung SY, Kim MS, et al. Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a World Health Organization pharmacovigilance study. Ophthalmology. 2025 Jan;132(1):62-78. Abstract
122. Dedania VS, Bakri SJ. Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. Curr Opin Ophthalmol. 2016 May;27(3):224-43. Abstract
123. Schlenker MB, Thiruchelvam D, Redelmeier DA. Intravitreal anti-vascular endothelial growth factor treatment and the risk of thromboembolism. Am J Ophthalmol. 2015 Sep;160(3):569-80.e5. Abstract
124. Cox JT, Eliott D, Sobrin L. Inflammatory complications of intravitreal anti-VEGF injections. J Clin Med. 2021 Mar 2;10(5):981.Full text Abstract
125. Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021 Jun;5(6):519-27.Full text Abstract
126. Tsang JY, Wright A, Carr MJ, et al. Risk of falls and fractures in individuals with cataract, age-related macular degeneration, or glaucoma. JAMA Ophthalmol. 2024 Feb 1;142(2):96-106.Full text Abstract
127. Aslanis S, Amrén U, Lindberg C, et al. Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen. Ophthalmol Retina. 2022 Jan;6(1):15-20.Full text Abstract
128. Lee J, Choi J, Yu SY, et al. Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment. Sci Rep. 2025 Mar 15;15(1):8952.Full text Abstract
129. Yiallouridou C, Acton JH, Banerjee S, et al. Pain related to intravitreal injections for age-related macular degeneration: a qualitative study of the perspectives of patients and practitioners. BMJ Open. 2023 Aug 16;13(8):e069625.Full text Abstract
130. Matamoros E, Maurel F, Léon N, et al. Quality of life in patients suffering from active exudative age-related macular degeneration: the EQUADE study. Ophthalmologica. 2015;234(3):151-9.Full text Abstract
131. van Nispen RM, Virgili G, Hoeben M, et al. Low vision rehabilitation for better quality of life in visually impaired adults. Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD006543.Full text Abstract
132. Jackson ML, Virgili G, Shepherd JD, et al. Vision rehabilitation preferred practice pattern®. Ophthalmology. 2023 Mar;130(3):P271-335.Full text
133. Riley M. Looking but not seeing. BMJ. 2023 Sep 20;382:1702.
134. Bittner AK, Yoshinaga PD, Rittiphairoj T, et al. Telerehabilitation for people with low vision. Cochrane Database Syst Rev. 2023 Jan 13;1(1):CD011019.Full text Abstract
Use of this content is subject to our disclaimer